Skip to main content
. 2022 Jul 8;6(7):e35636. doi: 10.2196/35636

Table 2.

Improvement in self-reported subjective symptoms after ≥30 days of Myndlift neurofeedback for users that scored in the healthy range, and separately for those that scored in the abnormal range (per conventional clinical cutoffs) at baseline.

Questionnaire and group at baseline (cutoff value) No. of sessions, mean (SD) Treatment duration (days), mean (SD) Change (points decreased), mean (SD) Change T value Change P valuea Effect size, d Users improved by ≥20%, n (%) Abnormal to healthy results, n (%)
12-item General Health Questionnaire (maximum score = 36)

Abnormal
(≥12; n=197)
53 (39.1) 94 (42.2) 7.8 (7.80) 13.94 <.001 0.99 139 (71) 113 (57)
Healthy
(<12; n=66)
52 (34.3) 84 (36.6) 1.0 (4.28) 1.90 .06 0.23 30 (45) N/Ab
ADHDc Rating Scale IV (for children; maximum score = 54): preliminary
Abnormal
(>36; n=7)
49 (19.7) 75 (32.8) 19.3 (7.99) 6.38 <.001 2.41 7 (100) 7 (100)
Healthy
(≤36; n=20)
53 (23.2) 102 (37.9) 7.9 (8.10) 4.36 <.001 0.98 14 (70) N/A
Adult ADHD Self-Report Scale (maximum score =24)

Abnormal
(≥14; n=56)
48 (25.6) 86 (41.5) 4.0 (3.81) 7.83 <.001 1.05 30 (54) 30 (54)
Healthy
(<14; n=56)
63 (35.7) 97 (37.2) 2.1 (2.14) 7.38 <.001 0.99 33 (59) N/A
7-item Generalized Anxiety Disorder scale (maximum score = 21)

Abnormal
(≥14; n=99)
52 (36.7) 87 (40.2) 6.4 (5.18) 12.39 <.001 1.24 82 (83) 68 (69)
Healthy
(<14; n=107)
55 (32.5) 97 (40.4) 1.3 (3.92) 3.43 .001 0.33 63 (59) N/A
9-item Patient Health Questionnaire (max imum score = 27)

Abnormal
(≥10; n=63)
57 (47.6) 88 (37.7) 6.2 (5.47) 8.94 <.001 1.13 45 (71) 38 (60)
Healthy
(<10; n=71)
57 (34.7) 95 (39.8) 1.5 (4.07) 3.04 .004 0.36 49 (69) N/A

aReported as Benjamini-Hochberg–adjusted P values.

bN/A: not applicable; healthy subjects are already within the healthy range.

cADHD: attention-deficit/hyperactivity disorder.